To begin the project, SIAPS helped coordinate regular planning meetings and discussions with the NTP’s Drugs and Supplies Management (DSM) sub-technical working group. SIAPS then facilitated collaboration among the NTP, the PD, WHO, and the GDF.
Tuberculosis is one of the world’s deadliest diseases, and multi-drug resistant TB has contributed significantly to the growing global threat of antimicrobial resistance. Yet in many of the countries most burdened by the disease, about half of those who have TB see private medicine vendors before any other health care professional. That can compound the … Read more
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines … Read more
Global partnerships and new models of TB care are crucial to success in the fight against multidrug-resistant tuberculosis (MDR-TB), according to speakers at a panel discussion on the White House National Action Plan for Combating MDR-TB. The plan, which was released in December, aims to treat 35% of all MDR-TB patients in the 10 countries with the highest TB burden … Read more
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline donation initiative, under which Janssen committed to providing free bedaquiline to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food and Drug Administration in more than 40 years, and is … Read more
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline donation initiative, under which Janssen committed to providing free bedaquiline to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food and Drug Administration in more than 40 years, and is … Read more
In September 2015, USAID’s Systems for Improved Access to Pharmaceuticals and Services (SIAPS) helped the Uzbek Ministry of Health (MOH) successfully complete a nationwide roll-out of QuanTB, a tuberculosis (TB) quantification tool. QuanTB is a downloadable desktop tool that transforms complicated calculations into a user-friendly dashboard displaying key information for managing medicines. By serving as … Read more
Three members of the SIAPS team presented at the 2015 Global Health Mini-University, held on Monday, March 2, at the George Washington University’s Cloyd Heck Marvin Center in Washington, DC. SIAPS Technical Associate Shirin Kakayeva presented on multidrug-resistant tuberculosis (MDR-TB) in Central Asia, highlighting the high MDR-TB burden in Tajikistan (13%) and Uzbekistan (23%) in particular. Kakayeva discussed the … Read more
By Shirin Kakayeva, SIAPS Technical Associate and Dr. Archil Salakaia, SIAPS Central Asia Portfolio Manager Uzbekistan is one of 18 high-priority countries in the WHO’s European region, and is among 27 high-burden multidrug-resistant tuberculosis (MDR-TB) countries in the world. As the uninterrupted supply of anti-TB medicines is necessary for the survival of TB patients, pharmaceutical management … Read more
The Philippines is one of the 22 countries worldwide with the highest tuberculosis (TB) rates and one of the 27 highest multidrug resistant tuberculosis (MDR-TB) burden countries. In late 2011, Quezon City Health Department (QCHD), with the support of the US Agency for International Development (USAID)-funded Systems for Improving Access to Pharmaceuticals and Services (SIAPS) Program, took … Read more
